Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593935 | 0.90 | THRA (0.49) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL941088 | 0.86 | KMT2A (0.54) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL7312871 | 0.84 | KMT2A (0.53) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL29153730 | 0.83 | HSD17B3 (0.57) | L3MBTL1KMT2AHPGDHSD17B10ALDH1A1 | |
| SCHEMBL11108445 | 0.82 | KMT2A (0.58) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL556208 | 0.81 | KMT2A (0.53) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL6496987 | 0.81 | KMT2A (0.53) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL338575 | 0.81 | KMT2A (0.53) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL5740022 | 0.79 | KDM4E (0.52) | L3MBTL1KMT2AKDM4EHPGDHSD17B10 | |
| SCHEMBL27627129 | 0.79 | KMT2A (0.46) | L3MBTL1KMT2AHPGDSMN1; SMN2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2512242-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-30 | — | — | EP | disclosed |
| US-9029545-B2 | Thienopyridine NOX2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-9029545-B2 | Thienopyridine NOX2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-9029545-B2 | Thienopyridine NOX2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| EP-2512242-A1 | NOVEL COMPOUNDS | Glaxo Wellcome Manufacturing Pte Ltd (SG) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252805-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252805-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252805-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| CN-101787000-B | M-stage kinesin inhibitor | KYOWA HAKKO KOGYO KK | 2011-08-03 | — | — | CN | disclosed |
| WO-2011075559-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2011-06-23 | — | — | WO | disclosed |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252805-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | L3MBTL1 3827/4885KMT2A 3182/4885KDM4E 3751/4885 |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | L3MBTL1 4174/4885KMT2A 974/4885KDM4E 599/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | L3MBTL1 4527/4885KMT2A 1846/4885KDM4E 2664/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | L3MBTL1 3220/4885KMT2A 322/4885KDM4E 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.